Solriamfetol hydrochloride

Solriamfetol hydrochloride (JZP-110 hydrochloride) is an orally active and selective dopamine and norepinephrine reuptake inhibitor with IC50s of 2.9 μM and 4.4 μM for dopamine and norepinephrine transporters, respectively. Solriamfetol hydrochloride has robust wake-promoting effects[1][2].

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

IC50: 2.9 μM (dopamine transporter) and 4.4 μM (norepinephrine transporter)[1]

Solriamfetol hydrochloride (JZP-110 hydrochloride) has the binding affinity for dopamine transporter (DAT; Ki=14,200 nM) and norepinephrine transporter (NET; Ki=3700 nM)[1].

Solriamfetol hydrochloride (JZP-110 hydrochloride; s.c.; 10, 30 mg/kg; eight consecutive 50-minute) increases DA and NE levels in the striatum and prefrontal cortex, respectively[1]. Solriamfetol hydrochloride (i.p.; 3, 10, 30, 100 mg/kg) dose dependently decreases the rate of responding. Solriamfetol of 100 mg/kg results in a significant decrease in response rate to approximately 40% of control[1]. solriamfetol hydrochloride (po; 35 mg/kg) produces a plasma Cmax of 23.1 μM[1]. Animal Model: Male Sprague-Dawley rats weighing 200-400 g[1] Dosage: 10 and 30 mg/kg Administration: S.c.; eight consecutive 50-minute Result: Increased DA and NE levels in the striatum and prefrontal cortex, respectively.

[1]. Baladi MG, et al. Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367-376.

[2]. Yang J, et al. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Rev Clin Pharmacol. 2019 Aug;12(8):723-728.